Skip to main content

Day: August 7, 2025

Live Ventures Reports Fiscal Third Quarter 2025 Financial Results

LAS VEGAS, Aug. 07, 2025 (GLOBE NEWSWIRE) — Live Ventures Incorporated (Nasdaq: LIVE) (“Live Ventures” or the “Company”), a diversified holding company, today announced financial results for its fiscal third quarter 2025 ended June 30, 2025.  Fiscal Third Quarter 2025 Key Highlights:Revenue was $112.5 million, compared to $123.9 million in the prior-year period Gross margin expanded to 34.0%, compared to 29.9% in the prior-year period, representing a 410 basis point improvement Operating income increased $6.9 million, or 607.6%, to $8.0 million, compared to $1.1 million in the prior-year period Net income increased $8.2 million to $5.4 million, and diluted earnings per share (“EPS”) were $1.24, compared to the prior-year period net loss of $2.9 million and diluted loss per share of $0.91. Net income for the third quarter of...

Continue reading

Runway Growth Finance Corp. Announces Third Quarter 2025 Total Distribution of $0.36 per Share

Distribution comprised of a $0.33 per share regular dividend and a $0.03 per share supplemental dividend MENLO PARK, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) — Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced that its Board of Directors has declared total distributions for the third quarter of $0.36 per share, comprised of a regular cash dividend of $0.33 per share and a supplemental dividend of $0.03 per share. The following shows the key dates of the third quarter 2025 dividend, including the supplemental dividend: Declaration Date: August 6, 2025Record Date: August 18, 2025Payment Date: September 2, 2025 Runway Growth generally intends to distribute, out of...

Continue reading

Bill Corl of Omega Laboratories Joins Cannabix Technologies Board of Directors

VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) is pleased to announce William (Bill) R. Corl has joined the board of directors of the Company. Mr. Corl is the Chief Executive Officer for Omega Laboratories, Inc., (“Omega”) one of the leading advanced specimen drug testing laboratories in the world. Omega and Cannabix have been working together since May 2024 under a strategic partnership and development agreement to advance commercialization of the Company’s Marijuana Breath Test (MBT) technology. Mr. Corl has spent the last twenty-six years creating and managing technology solutions in the diagnostic testing, media and radiology industries. Mr. Corl has spent the last twenty plus years helping advance the drug screening...

Continue reading

SS Innovations Reports Second Quarter 2025 Financial Results

Record Quarterly Revenue of $10.0 Million Driven by Higher SSi Mantra 3 Unit Sales Gross Profit More than Tripled, Driven by Gross Margin Expansion and Revenue Growth    FORT LAUDERDALE, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) — SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced unaudited financial results for the three and six months ended June 30, 2025.   The Company also filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, with the Securities and Exchange Commission on August 6, 2025. Second Quarter 2025 OverviewRevenue increased 121.8% to $10.0 million from $4.5 million in the second quarter of 2024. Gross margin...

Continue reading

IQST – IQSTEL and Cycurion (CYCU) Sign MOU for Equity Exchange and Alliance to Build a Next-Gen AI-Driven Powerhouse with Half of the Stock to be Distributed as a Dividend to Shareholders

Both Companies combined have Invested Millions of Dollars over the last 5 years into Proprietary AI assets and technologies. NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — IQSTEL Inc. (NASDAQ: IQST) (“IQSTEL”) and Cycurion Inc. (NASDAQ: CYCU) (“Cycurion”) today announced the signing of a Memorandum of Understanding (MOU) to become mutual equity partners following a planned $1 million stock exchange, with half of each company’s exchanged shares to be distributed as a dividend to enhance shareholder value. This milestone marks a significant step in the two companies’ collaboration and sets the stage for creating a powerhouse in AI-driven cybersecurity for the global telecommunications industry. This transaction is designed to unlock shareholder value, while being strategically timed for both companies as the products and services of...

Continue reading

PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights

PMV will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review Phase 2 PYNNACLE clinical trial interim analysis    Interim analysis will include data for approximately 65 patients with at least 18 weeks of follow-up  Cash, cash equivalents, and marketable securities of $148.3 million as of June 30, 2025, providing expected cash runway to end of 2026PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the second quarter ended June 30, 2025, and provided a corporate update. PMV Pharma will host an investor webinar on Wednesday, September 10, 2025 at 8:00 AM ET to review...

Continue reading

Intelligent Bio Solutions Announces Preliminary Fiscal Fourth Quarter Revenue with Double-Digit Sequential and Year-Over-Year Growth and Strong Operational Momentum

Company anticipates fiscal fourth quarter sequential and year-on-year revenue growth of approximately 16% Company advanced efforts to secure U.S. FDA 510(k) clearance for planned U.S. market entry and strengthened global readiness through system upgrades and localization NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results and key operational highlights for the fiscal fourth quarter and full-year ended June 30, 2025. “Fiscal 2025 represented a year of disciplined execution and strategic investment. For the fiscal fourth quarter, we expect to report another quarter of sequential and year-over-year...

Continue reading

NetworkNewsAudio Announces Audio Press Release (APR) on Expanding Neural Tech Leadership in Booming AI Wearables Market

AUSTIN, Texas, Aug. 07, 2025 (GLOBE NEWSWIRE) —  via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Neural Tech Drives the Growth of the AI Wearables Market,” featuring Wearable Devices Ltd. (NASDAQ: WLDS). To hear the NetworkNewsAudio version, visit https://nnw.fm/Cr4Sz To read the original editorial, visit https://nnw.fm/OZmoJ Wearable Devices Ltd. is emerging as a leading innovator in the rapidly expanding AI-powered wearables sector, which is projected to grow from $21.2 billion in 2022 to over $260 billion by 2032. At the heart of the company’s offering is its proprietary neural input technology, including the Mudra Link wristband and the LMM platform, which enable intuitive, touchless control of digital devices through subtle wrist signals. These innovations support hands-free interaction with AR/VR...

Continue reading

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without Modification

–        Final Analysis Anticipated by Year-End Upon Occurrence of 80 Events        – NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Independent Data Monitoring Committee (IDMC) has completed a pre-specified analysis of the Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML), and has issued a positive recommendation to continue the trial without modification. The IDMC concluded that the risk-benefit profile of GPS supports continued evaluation under the current study protocol. No safety concerns were identified, and available efficacy data were consistent with expectations...

Continue reading

Aureus Greenway Holdings , Inc. Regains Compliance with Nasdaq Minimum Bid Price Rule

Kissimmee, FL, Aug. 07, 2025 (GLOBE NEWSWIRE) — Aureus Greenway Holdings Inc. (the “Company”, “Aureus Greenway”, “we”, “us”, “our”) (Nasdaq: AGH), an owner and operator of daily fee golf country clubs in the state of Florida, announced today that on August 6, 2025, the Company received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) that for the ten consecutive business days from June 23, 2025, to August 5, 2025, the closing bid price of the Company’s common stock has been at $1.00 per share or greater. Accordingly, Aureus Greenway has regained compliance with Nasdaq Listing Rule 5550(a)(2). About Aureus Greenway Holdings Inc. Aureus Greenway Holdings Inc. (Nasdaq: AGH), owns and operates daily fee golf country clubs in the state of Florida that are designed to appeal to a wide-ranging population. The...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.